At the news
? BULLISHIMPACT 7/10 8-K filed Apr 27, 2026 at 08:16 ET
Oncolytics Biotech announced alignment with the FDA on a randomized controlled pivotal trial design for pelareorep in metastatic squamous cell carcinoma of the anal canal (SCAC), a rare cancer with no approved therapies post-first-line treatment. The study leverages strong prior data showing improved duration of response and survival versus standard of care.
- FDA alignment achieved on pivotal randomized controlled trial for pelareorep in metastatic SCAC
- Study targets post-standard-of-care population with no FDA-approved options
- Prior data showed 15.5 vs 9.5 month median duration of response and 82% vs 45.7% 12-month survival vs standard of care
- Trial design may support both accelerated and full approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access